Lunesta (Eszopiclone) Safety in Adults 65 and Older

Why Geriatric Dosing Differs from Standard Adult Dosing

Older adults metabolize eszopiclone more slowly than younger patients, which directly affects safety. The FDA-approved prescribing information sets the geriatric starting dose at 1 mg, compared to 2 mg for younger adults. Maximum recommended dose is 2 mg for patients 65 and older. This is not arbitrary.

Pharmacokinetic studies show that eszopiclone's elimination half-life extends to roughly 9 hours in elderly subjects, compared to approximately 6 hours in healthy younger adults [1]. The area under the curve (AUC) increases by about 41% in older patients, meaning more drug circulates for longer. Reduced hepatic blood flow and lower CYP3A4 enzyme activity both contribute. Renal clearance also declines with age, though eszopiclone is primarily hepatically metabolized.

The clinical consequence is straightforward: a standard 2 mg or 3 mg dose in a 70-year-old produces plasma concentrations that remain at pharmacologically active levels well into the next morning. That residual drug exposure drives many of the safety problems discussed below. Prescribers who start at 1 mg and titrate only if needed can reduce the risk of next-day impairment significantly [2].

Falls and Fracture Risk: The Central Safety Concern

Falls represent the single most consequential adverse event associated with Z-drug use in older adults. A dose-response relationship exists. A meta-analysis published in the BMJ found that sedative-hypnotic use increased fall risk by 40-70% in community-dwelling older adults, with the highest risk occurring during the first two weeks of therapy.

The mechanism involves several overlapping pathways. Eszopiclone acts on GABA-A receptors, which impairs balance, slows reaction time, and blunts proprioceptive feedback. Nocturia, which is common in adults over 65, compounds the problem. A patient who takes eszopiclone at 10 PM and rises to use the bathroom at 2 AM is navigating a dark environment with impaired motor coordination.

Hip fractures deserve specific mention. The American Geriatrics Society 2023 updated Beers Criteria lists eszopiclone, zolpidem, and zaleplon as potentially inappropriate medications in older adults, citing "minimal improvement in sleep latency and duration" relative to the risk of falls, emergency department visits, hospitalizations, motor vehicle crashes, and fractures. A large cohort study using Medicare claims data showed that new Z-drug prescriptions in adults over 65 were associated with a 2.55-fold increase in hip fracture within 30 days of initiation.

The practical takeaway: if eszopiclone is prescribed, the lowest effective dose should be used for the shortest practical duration, and fall-prevention strategies (nightlights, clear pathways, non-slip footwear, bedside urinals) should be discussed at the same visit.

Cognitive and Neuropsychiatric Effects

The relationship between Z-drugs and cognitive decline in older adults has been studied extensively but remains contested. Short-term cognitive effects are well-documented. Eszopiclone at any dose can cause next-morning impairment in attention, memory, and executive function, and these effects are amplified in older adults because of prolonged drug exposure [3].

Long-term cognitive effects are harder to pin down. A prospective cohort study published in the BMJ reported a dose-dependent association between benzodiazepine and Z-drug use and incident dementia, with a 1.5-fold increased risk in users taking these medications for more than 3 months. Whether this reflects a causal relationship, a protopathic bias (insomnia itself may be a prodromal symptom of neurodegeneration), or confounding by indication remains debated.

What is not debated: eszopiclone can cause complex sleep behaviors. The FDA issued a boxed warning in 2019 for all three Z-drugs after reports of sleepwalking, sleep-driving, and other activities performed without full awareness. A small number of these episodes resulted in serious injuries and deaths. Older adults with baseline cognitive impairment or polypharmacy are theoretically at higher risk, though the absolute incidence is low.

Delirium is another concern specific to hospitalized or acutely ill older adults. The American Geriatrics Society's Clinical Practice Guideline for Postoperative Delirium recommends avoiding sedative-hypnotics in the perioperative setting for patients 65 and older. Eszopiclone should be held or tapered before elective surgery whenever possible.

Drug Interaction Burden in Polypharmacy

Adults 65 and older take a median of 5 prescription medications. Eszopiclone is metabolized primarily by CYP3A4, which makes it susceptible to pharmacokinetic interactions with a long list of commonly prescribed drugs [4].

CYP3A4 inhibitors raise eszopiclone plasma levels. The prescribing information specifically notes that co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased eszopiclone AUC by 2.2-fold. Clinically relevant CYP3A4 inhibitors that geriatric patients may encounter include clarithromycin, itraconazole, ritonavir, diltiazem, verapamil, and grapefruit juice. When a strong CYP3A4 inhibitor is co-administered, the FDA label recommends a starting dose of 1 mg, with a maximum of 2 mg. For a geriatric patient already starting at 1 mg, this means no room for dose escalation.

Pharmacodynamic interactions matter just as much. Combining eszopiclone with opioids (even low-dose oxycodone or tramadol for arthritis pain), benzodiazepines, gabapentinoids (pregabalin, gabapentin), muscle relaxants, or first-generation antihistamines (diphenhydramine, hydroxyzine) creates additive CNS depression. The resulting sedation and respiratory depression can be life-threatening. A retrospective analysis of VA health system data demonstrated that concurrent opioid-benzodiazepine/Z-drug use was associated with a 3.86-fold increase in overdose death risk. Alcohol, even in moderate quantities, compounds these effects.

Medication reconciliation before prescribing eszopiclone to any older patient is not optional. Every prescriber should review the full medication list, including over-the-counter sleep aids and supplements.

What the Key Trials Actually Show in Older Adults

The largest published trial of eszopiclone for chronic insomnia ran for 6 months and was led by Krystal et al., published in Sleep in 2003. The study enrolled 788 adults (ages 21-69) with primary insomnia and randomized them to eszopiclone 3 mg or placebo nightly for 6 months [1]. Eszopiclone reduced subjective sleep latency by approximately 25-30 minutes compared to placebo and improved sleep maintenance. Tolerance did not develop over the 6-month period.

A critical limitation: only a subset of participants were older adults, and the 3 mg dose used in the trial exceeds the recommended geriatric maximum of 2 mg. The study excluded patients with significant medical comorbidities, polypharmacy, and cognitive impairment, which are the defining features of real-world geriatric insomnia patients.

A separate 2-week study specifically enrolling elderly patients with insomnia (N=231, ages 65-86) showed that eszopiclone 2 mg reduced subjective wake time after sleep onset by roughly 20 minutes versus placebo. The most common adverse events were unpleasant taste (reported by 17% on drug vs. 4% on placebo), headache, and infection. Fall rates were not separately reported, a notable gap.

The evidence base for eszopiclone in older adults, while showing modest efficacy, is thinner than many prescribers realize. The Cochrane review on sedative hypnotics for insomnia in older people concluded that while these drugs improve sleep, the magnitude of benefit is small (sleep latency reduced by 25 minutes) and "the increased risk of adverse events is statistically significant."

Dr. Sharon Inouye, Professor of Medicine at Harvard Medical School and developer of the Confusion Assessment Method, has stated: "Non-pharmacological treatments for insomnia should always be first-line in older adults, and the bar for starting a sedative-hypnotic should be high."

Non-Pharmacological Alternatives That Should Come First

The American College of Physicians clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for chronic insomnia in all adults. This recommendation applies with even greater force to older patients.

CBT-I has a strong evidence base in geriatric populations. A randomized trial of CBT-I in 79 adults aged 55 and older demonstrated sustained improvements in sleep efficiency and total sleep time at 24-month follow-up, without medication side effects. The effect sizes rival or exceed those of pharmacotherapy, and benefits persist after treatment ends, unlike medication effects.

CBT-I components include sleep restriction therapy, stimulus control, sleep hygiene education, and cognitive restructuring of dysfunctional beliefs about sleep. Delivery formats include in-person therapy (4-6 sessions), telehealth sessions, and digital platforms such as Pear Therapeutics' Somryst (now FDA-cleared as a prescription digital therapeutic).

Other non-pharmacological strategies with evidence include bright light therapy (morning exposure for circadian rhythm reinforcement), exercise (30 minutes of moderate activity, but not within 4 hours of bedtime), and addressing underlying contributors such as untreated pain, nocturia, sleep apnea, restless legs syndrome, and depression. Many geriatric insomnia patients improve substantially when these contributors are identified and managed.

Deprescribing Eszopiclone: A Structured Approach

Stopping eszopiclone abruptly can trigger rebound insomnia, anxiety, and in rare cases, withdrawal seizures. Gradual taper is the standard of care.

The Canadian Deprescribing Network's evidence-based guideline provides a practical framework. For patients taking eszopiclone nightly, a reasonable taper involves reducing the dose by 25-50% every 1-2 weeks. A patient on 2 mg nightly might move to 1 mg nightly for two weeks, then 1 mg every other night for two weeks, then discontinuation. The entire process typically spans 4-8 weeks.

During taper, expect a transient worsening of sleep. Patients should be counseled that 1-2 weeks of increased difficulty falling asleep or staying asleep is normal and will resolve. Concurrent initiation of CBT-I during the taper period improves success rates substantially. A randomized trial of supervised benzodiazepine/Z-drug withdrawal plus CBT-I in older adults showed that 67% of participants in the CBT-I group were medication-free at 12 months compared to 37% receiving taper alone.

Key indicators for deprescribing include: use exceeding 4 weeks with no planned stop date, presence of daytime drowsiness or cognitive complaints, a history of falls or near-falls, concurrent use of other CNS depressants, or patient preference to stop. Age over 65 alone is sufficient reason to reevaluate ongoing use, per Beers Criteria recommendations [5].

When Eszopiclone May Still Be Appropriate

Not every older adult should avoid eszopiclone. Short-term use (2-4 weeks) at 1 mg may be reasonable in specific clinical scenarios: acute situational insomnia following bereavement, hospitalization recovery, or jet lag in a cognitively intact patient without fall risk factors, where CBT-I is not accessible or has been tried and failed.

The prescribing decision should involve explicit risk-benefit discussion. The number needed to treat (NNT) for meaningful improvement in sleep latency with Z-drugs in older adults is approximately 13, while the number needed to harm (NNH) for an adverse event is approximately 6 [6]. These numbers favor caution. Any prescription should include a planned stop date documented in the chart, not an open-ended refill.

Ongoing monitoring should include assessment for falls, daytime somnolence, cognitive changes, complex sleep behaviors, and unpleasant taste (the most common reason patients self-discontinue). Follow-up within 2-4 weeks of initiation is a minimum standard. Prescriptions for older adults should specify 1 mg tablets with no refills without a reassessment visit, a prescribing discipline that reduces inadvertent chronic use.